April 16, 2024
all-antibody

Immune Factors That Influence The Persistence of Antiphospholipid

Epidemiological, scientific and immune elements that affect the persistence of antiphospholipid antibodies in leprosy.

Antiphospholipid antibodies (aPL) are described in people with leprosy with out the scientific options of antiphospholipid antibody syndrome (APS), a situation involving thromboembolic phenomena. We’ve got described the persistence of those antibodies for over 5 years in sufferers with leprosy after particular remedy.To find out whether or not epidemiological, scientific and immunological elements performed a job within the long-term persistence of aPL antibodies in leprosy sufferers after multidrug remedy (MDT) had completed.

METHODS

The research pattern consisted of 38 sufferers with a analysis of leprosy being adopted up on the Dermatology and Venereology Outpatient Division on the Alfredo da Matta Basis (FUAM) in Manaus, AM. ELISA was used to detect anticardiolipin (aCL) and anti-β2 glycoprotein I (anti-β2GPI) antibodies. Sufferers have been reassessed on common of 5 years after particular remedy for the illness (MDT) had been accomplished.

RESULTS

Persistence of aPL antibodies among the many 38 leprosy sufferers was 84% (32/38), and all had the IgM isotype. Imply age was 48.1 ± 15.9 years, and 23 (72.0%) have been male. The lepromatous kind (LL) of leprosy was the commonest (n = 16, 50%). Reactional episodes have been noticed in three sufferers (9.4%). Eighteen (47.37%) have been nonetheless taking treatment (prednisone and/or thalidomide).

 

Imply IgM ranges have been 64 U/mL for aCL and 62 U/mL for anti-β2GPI. Within the multivariate binary logistic regression the next variables confirmed a big affiliation: age (p = 0.045, OR = 0.91 and CI 95% 0.82-0.98), LL scientific presention (p = 0.034; OR = 0.02 and CI 95% = 0.0-0.76) and bacterial index (p = 0.044; OR = 2.74 and CI 95% = 1.03-7.33). We didn’t discover affiliation between prednisone or thalidomide doses and positivity for aPL (p = 0.504 and p = 0.670, respectively).

 

No variations within the variables vascular thrombosis, being pregnant morbidity, diabetes, smoking and alcoholism have been discovered between aPL-positive and aPL-negative sufferers.Persistence of positivity for aPL antibodies was influenced by age, scientific presentation and bacterial index. Nonetheless, additional research are wanted to elucidate the explanation for this persistence, the position performed by aPL antibodies within the illness and the B cell lineages liable for era of those antibodies.

all-antibody
all-antibody

Anti-Human IL-4 Antibody

101-M508 100 µg
EUR 399
Description: Interleukin 4 (IL-4) is a pleiotropic cytokine produced by activated T cells, mast cells, and basophils. It was initially identified as a B cell differentiation factor (BCDF), as well as a B cell stimulatory factor (BSF1). IL-4 has since been shown to have multiple biological effects on hematopoietic and non-hematopoietic cells, including B and T cells, monocytes, macrophages, mast cells, myeloid and erythroid progenitors, fibroblasts, and endothelial cells. Rat, mouse and human IL-4 are species-specific in their activities.

Anti-human IL-4 antibody

STJ15100045 250 µg
EUR 403.2
Description: This monoclonal antibody enables sensitive and specific detection of human IL-4 in immunoassays such as ELISA and ELISpot.

Anti-human IL-4 antibody

STJ15100046 250 µg
EUR 440.4
Description: This monoclonal antibody enables sensitive and specific detection of human IL-4 in immunoassays such as ELISA and ELISpot.

Anti‐Human IL‐17A

E2790213 100ul
EUR 225
Description: Available in various conjugation types.

IL-4, Human

E34M006H 5 μg
EUR 155

Human IL-4

GWB-CB2917 0.01 mg Ask for price

Human IL-4

gAP-0227 1mg
EUR 450

Human Interleukin-4 (IL-4) Antibody

32184-05111 150 ug
EUR 215

anti- IL-4 antibody

FNab09861 100µg
EUR 658.5
Description: Antibody raised against IL-4

anti- IL-4 antibody

FNab04278 100µg
EUR 702
Description: Antibody raised against IL-4

anti- IL-4 antibody

FNab04279 100µg
EUR 702
Description: Antibody raised against IL-4

anti- IL-4 antibody

LSMab09861 100 ug
EUR 463.2

Anti-IL-4 Antibody

ER1706-55 100ul
EUR 189
Description: Interleukin-4 (IL-4), also designated B cell stimulatory factor-1, is a glycosylated cytokine secreted by activated T lymphocytes, basophils and mast cells. The secreted IL-4 protein promotes the growth and differentiation of cells that participate in immune defense by favoring such events as the expansion of the Th2 lineage relative to Th1 cells. These T helper cell subsets are defined by their pattern of cytokine secretion: Th1 cells secrete IL-2, TNFβ and IFN-γ, while Th2 cells secrete IL-4, IL-5 and IL-10. Another key immunological function of IL-4 is to induce immunoglobulin class switching. IL-4 has been shown to induce the production of IgE and enhance IgG4 secretion by B cells, but suppress the production of IgM, IgA, IgG1, IgG2, and IgG3. It has been determined that Stat6 is rapidly tyrosine phosphorylated following stimulation of IL-3 or IL-4, but is not detectably phosphorylated following stimulation with IL-2, IL-12 or erythropoietin.

Anti-IL-4 Antibody

E38A8953 100ug/100ul
EUR 225
Description: Available in various conjugation types.

Anti-IL-4 Antibody

E38A8961 100ug/100ul
EUR 225
Description: Available in various conjugation types.

Anti-IL-4 antibody

PAab04278 100 ug
EUR 494.4

Anti-IL-4 antibody

STJ96510 200 µl
EUR 236.4
Description: Rabbit polyclonal to IL-4.

Anti-IL-4 antibody

STJ93699 200 µl
EUR 236.4
Description: Rabbit polyclonal to IL-4.

Anti-IL-4 antibody

STJ93700 200 µl
EUR 236.4
Description: Rabbit polyclonal to IL-4.

PE Anti-Human IL-4 Antibody

DL22181F-20Tests 20Tests
EUR 222.5
Description: IL-4 is a pleiotropic cytokine that is produced by activated T cells, mast cells, and basophils. IL-4 elicits many different biological responses but has two dominant functions. The first is regulating differentiation of naïve CD4+ T cell to the Th2 type. Th2 cells produce IL-4, IL-5, IL-10, and IL-13, which tend to favor a humoral immune response while suppressing a cell-mediated immune response controlled by Th1 cells. The second is regulating IgE and IgG1 production by B cells.

PE Anti-Human IL-4 Antibody

DL22181F-50Tests 50Tests
EUR 320
Description: IL-4 is a pleiotropic cytokine that is produced by activated T cells, mast cells, and basophils. IL-4 elicits many different biological responses but has two dominant functions. The first is regulating differentiation of naïve CD4+ T cell to the Th2 type. Th2 cells produce IL-4, IL-5, IL-10, and IL-13, which tend to favor a humoral immune response while suppressing a cell-mediated immune response controlled by Th1 cells. The second is regulating IgE and IgG1 production by B cells.

APC Anti-Human IL-4 Antibody

DL22182F-20Tests 20Tests
EUR 245
Description: IL-4 is a pleiotropic cytokine that is produced by activated T cells, mast cells, and basophils. IL-4 elicits many different biological responses but has two dominant functions. The first is regulating differentiation of naïve CD4+ T cell to the Th2 type. Th2 cells produce IL-4, IL-5, IL-10, and IL-13, which tend to favor a humoral immune response while suppressing a cell-mediated immune response controlled by Th1 cells. The second is regulating IgE and IgG1 production by B cells.

APC Anti-Human IL-4 Antibody

DL22182F-50Tests 50Tests
EUR 357.5
Description: IL-4 is a pleiotropic cytokine that is produced by activated T cells, mast cells, and basophils. IL-4 elicits many different biological responses but has two dominant functions. The first is regulating differentiation of naïve CD4+ T cell to the Th2 type. Th2 cells produce IL-4, IL-5, IL-10, and IL-13, which tend to favor a humoral immune response while suppressing a cell-mediated immune response controlled by Th1 cells. The second is regulating IgE and IgG1 production by B cells.

Rat Anti-Human IL-4, Antibody

GWB-ACBDBA 0.5 mg Ask for price

Rat Anti-Human IL-4, Antibody

GWB-600465 0.5 mg Ask for price

Rat Anti-Human IL-4, Antibody

GWB-C54D97 0.5 mg Ask for price

FITC Anti-Human IL-4 Antibody

DL22180F-20Tests 20Tests
EUR 222.5
Description: IL-4 is a pleiotropic cytokine that is produced by activated T cells, mast cells, and basophils. IL-4 elicits many different biological responses but has two dominant functions. The first is regulating differentiation of naïve CD4+ T cell to the Th2 type. Th2 cells produce IL-4, IL-5, IL-10, and IL-13, which tend to favor a humoral immune response while suppressing a cell-mediated immune response controlled by Th1 cells. The second is regulating IgE and IgG1 production by B cells.

FITC Anti-Human IL-4 Antibody

DL22180F-50Tests 50Tests
EUR 320
Description: IL-4 is a pleiotropic cytokine that is produced by activated T cells, mast cells, and basophils. IL-4 elicits many different biological responses but has two dominant functions. The first is regulating differentiation of naïve CD4+ T cell to the Th2 type. Th2 cells produce IL-4, IL-5, IL-10, and IL-13, which tend to favor a humoral immune response while suppressing a cell-mediated immune response controlled by Th1 cells. The second is regulating IgE and IgG1 production by B cells.

Purified Anti-Human IL-4 Antibody

DL22179F-100ug 100μg
EUR 290
Description: IL-4 is a pleiotropic cytokine that is produced by activated T cells, mast cells, and basophils. IL-4 elicits many different biological responses but has two dominant functions. The first is regulating differentiation of naïve CD4+ T cell to the Th2 type. Th2 cells produce IL-4, IL-5, IL-10, and IL-13, which tend to favor a humoral immune response while suppressing a cell-mediated immune response controlled by Th1 cells. The second is regulating IgE and IgG1 production by B cells.

Purified Anti-Human IL-4 Antibody

DL22179F-25ug 25μg
EUR 177.5
Description: IL-4 is a pleiotropic cytokine that is produced by activated T cells, mast cells, and basophils. IL-4 elicits many different biological responses but has two dominant functions. The first is regulating differentiation of naïve CD4+ T cell to the Th2 type. Th2 cells produce IL-4, IL-5, IL-10, and IL-13, which tend to favor a humoral immune response while suppressing a cell-mediated immune response controlled by Th1 cells. The second is regulating IgE and IgG1 production by B cells.

mAb mouse anti-human IL-4

CT253 0.5 mg
EUR 312

mouse anti-human IL-4 mAb

E409C13-m100 100μL
EUR 395
Description: Available in various conjugation types.

Rabbit anti-Human IL-4(CAP)

RM17744 1000μg Ask for price

Rabbit anti-Human IL-4(DET)

RM17745 100μg Ask for price

Mouse Monoclonal anti-human IL-4

hAP-0404 100ug
EUR 250

Sheep Polyclonal anti-human IL-4

hAP-5265 50ug
EUR 400

human anti-human IL-5 mAb

E4A09D05 50ug
EUR 255
Description: Available in various conjugation types.

human anti-human IL-2 mAb

E409C12-h100 100μL
EUR 395
Description: Available in various conjugation types.

human anti-human IL-5 mAb

E409C14-h100 100μL
EUR 395
Description: Available in various conjugation types.

human anti-human IL-8 mAb

E409C16-h100 100μL
EUR 395
Description: Available in various conjugation types.

human anti-human IL-1β mAb

E409C11-h100 100μL
EUR 395
Description: Available in various conjugation types.

human anti-human IL-10 mAb

E409C17-h100 100μL
EUR 395
Description: Available in various conjugation types.

Interleukin-4 (IL-4) Human

GWB-2A39E4 0.01 mg Ask for price

Human Interleukin-4 (IL-4)

1-CSB-EP011659HU
  • Ask for price
  • Ask for price
  • Ask for price
  • Ask for price
  • Ask for price
  • Ask for price
  • 100ug
  • 10ug
  • 1MG
  • 200ug
  • 500ug
  • 50ug
Description: Recombinant Human Interleukin-4(IL-4) expressed in E.coli

IL-4, Interleukin-4, human

RC212-15 5ug
EUR 125.26

human anti-human IL-12/IL-23 p40 mAb(3H2)

E4A09D33-3H2 50ug
EUR 275
Description: Biotin-Conjugated, FITC-Conjugated , AF350 Conjugated , AF405M-Conjugated ,AF488-Conjugated, AF514-Conjugated ,AF532-Conjugated, AF555-Conjugated ,AF568-Conjugated , HRP-Conjugated, AF405S-Conjugated, AF405L-Conjugated , AF546-Conjugated, AF594-Conjugated , AF610-Conjugated, AF635-Conjugated , AF647-Conjugated , AF680-Conjugated , AF700-Conjugated , AF750-Conjugated , AF790-Conjugated , APC-Conjugated , PE-Conjugated , Cy3-Conjugated , Cy5-Conjugated , Cy5.5-Conjugated , Cy7-Conjugated Antibody

human anti-human IL-12/IL-23 p40 mAb(5N9)

E4A09D33-5N9 50ug
EUR 275
Description: Biotin-Conjugated, FITC-Conjugated , AF350 Conjugated , AF405M-Conjugated ,AF488-Conjugated, AF514-Conjugated ,AF532-Conjugated, AF555-Conjugated ,AF568-Conjugated , HRP-Conjugated, AF405S-Conjugated, AF405L-Conjugated , AF546-Conjugated, AF594-Conjugated , AF610-Conjugated, AF635-Conjugated , AF647-Conjugated , AF680-Conjugated , AF700-Conjugated , AF750-Conjugated , AF790-Conjugated , APC-Conjugated , PE-Conjugated , Cy3-Conjugated , Cy5-Conjugated , Cy5.5-Conjugated , Cy7-Conjugated Antibody

human anti-human IL-12/IL-23 p40 mAb(1G11)

E4A09D33-1G11 50ug
EUR 275
Description: Biotin-Conjugated, FITC-Conjugated , AF350 Conjugated , AF405M-Conjugated ,AF488-Conjugated, AF514-Conjugated ,AF532-Conjugated, AF555-Conjugated ,AF568-Conjugated , HRP-Conjugated, AF405S-Conjugated, AF405L-Conjugated , AF546-Conjugated, AF594-Conjugated , AF610-Conjugated, AF635-Conjugated , AF647-Conjugated , AF680-Conjugated , AF700-Conjugated , AF750-Conjugated , AF790-Conjugated , APC-Conjugated , PE-Conjugated , Cy3-Conjugated , Cy5-Conjugated , Cy5.5-Conjugated , Cy7-Conjugated Antibody

Anti-Interleukin-4 (IL-4) Antibody

Y108183 50 μg
EUR 455

rec IL-4 (human)

H-9630.0002 2.0µg
EUR 313.2

rec IL-4 (human)

H-9630.0010 10.0µg
EUR 1140

Human IL-4 Protein

abx060798-20ug 20 ug
EUR 560.4

Human IL-4 protein

PRP100273-100ug 100 μg
EUR 1029
Description: Human IL-4 protein, expressed in E. coli

Human IL-4 protein

PRP100273-1mg 1 mg
EUR 7139
Description: Human IL-4 protein, expressed in E. coli

Human IL-4 protein

PRP100273-20ug 20 μg
EUR 509
Description: Human IL-4 protein, expressed in E. coli

Human IL-4 protein

PRP2017-100ug 100 μg
EUR 429
Description: Human IL-4 protein, expressed in HEK293 Cells

Human IL-4 protein

PRP2017-10ug 10 μg
EUR 59
Description: Human IL-4 protein, expressed in HEK293 Cells

Human IL-4 protein

PRP2017-1mg 1 mg
EUR 3739
Description: Human IL-4 protein, expressed in HEK293 Cells

Human IL-4 protein

PRP2017-50ug 50 μg
EUR 249
Description: Human IL-4 protein, expressed in HEK293 Cells

Recombinant Human IL-4

6486 5 µg
EUR 194

IL-4, human recombinant

4137-10 each
EUR 333.6

IL-4, human recombinant

4137-1000 each
EUR 4444.8

IL-4, human recombinant

4137-50 each
EUR 836.4

Recombinant Human IL-4

HEILP-0401 5ug Ask for price

Recombinant Human IL-4

P0052 100ug
EUR 626.83
Description: Recombinant Human protein for IL-4

Recombinant Human IL-4

SJB02-03 10µg/vial
EUR 342

Recombinant Human IL-4

SJB02-05 100µg/vial
EUR 864

Recombinant Human IL-4

SJB02-06 30µg/vial
EUR 516

Recombinant human IL-4

rcyec-hil4 10 µg
EUR 156.45

human IL-10 / IL-4 (without plate)

M874022001 1 unit
EUR 244.37

human IL-10 / IL-4 (without plate)

M874030001 1 unit
EUR 266.67

Human IL-4 Antibody Pair Set

ABPR-ZB073 5 plates, 15 plates Ask for price
Description: Quantitative determination of Human IL-4

Human IL-4 ELISA antibody pair

CT742-10 10-plate
EUR 656.4

Dissecting the molecular foundation of excessive viscosity of monospecific and bispecific IgG antibodies.

Some antibodies exhibit elevated viscosity at excessive concentrations, making them poorly fitted to therapeutic functions requiring administration by injection akin to subcutaneous or ocular supply. Right here we studied an anti-IL-13/IL-17 bispecific IgG4 antibody, which has anomalously excessive viscosity in comparison with its mum or dad monospecific antibodies.

 

  • The viscosity of the bispecific IgG4 in answer was decreased by solely ~30% within the presence of NaCl, suggesting electrostatic interactions are inadequate to completely clarify the drivers of viscosity. Intriguingly, addition of arginine-HCl diminished the viscosity of the bispecific IgG4 by ~50% to its mum or dad IgG degree.
  • These information counsel that past electrostatics, further varieties of interactions akin to cation-π and/or π-π might contribute to excessive viscosity extra considerably than beforehand understood. Molecular dynamics simulations of antibody fragments within the blended answer of free arginine and specific water have been performed to establish hotspots concerned in self-interactions.
  • Uncovered floor fragrant amino acids displayed an elevated variety of contacts with arginine. Mutagenesis of the vast majority of fragrant residues pinpointed by molecular dynamics simulations successfully decreased the answer’s viscosity when examined experimentally.
  • This mutational methodology to scale back the viscosity of a bispecific antibody was prolonged to a monospecific anti-GCGR IgG1 antibody with elevated viscosity. In all circumstances, level mutants have been readily recognized that each diminished viscosity and retained antigen-binding affinity.
  • These research show a brand new method to mitigate excessive viscosity of some antibodies by mutagenesis of surface-exposed fragrant residues on complementarity-determining areas that will facilitate some scientific functions.

PLGF (PGF) (PlGF-1/2) mouse monoclonal antibody, clone 178/G10, Biotin, Purified

DM3525B 50 µg Ask for price

Mouse PlGF Recombinant Protein

M30-019 5 µg
EUR 136.5
Description: Placenta growth factor (PlGF) is a member of the vascular endothelial growth factor (VEGF) family of growth factors. PlGF and VEGF share primary structural as well as limited amino acid sequence homology with the A and B chains of PDGF. All eight cysteine residues involved in intra and interchain disulfides are conserved among these growth factors. As a result of alternative splicing, three PlGF RNAs encoding monomeric human PlGF1, PlGF2 and PlGF3 isoform precursors containing 149, 179 and 219 amino acid residues, respectively, have been described. In normal mouse tissues, only one mouse PlGF mRNA encoding the equivalent of human PlGF2 has been identified. Mouse PlGF shares 65% amino acid identity with human PlGF2. The gene for PlGF has been mapped to mouse chromosome 12 and human chromosome 14. PlGF binds with high affinity to Flt1, but not to Flk1/KDR.

Mouse PlGF Recombinant Protein

M30-019S 2 µg
EUR 73.5
Description: Placenta growth factor (PlGF) is a member of the vascular endothelial growth factor (VEGF) family of growth factors. PlGF and VEGF share primary structural as well as limited amino acid sequence homology with the A and B chains of PDGF. All eight cysteine residues involved in intra and interchain disulfides are conserved among these growth factors. As a result of alternative splicing, three PlGF RNAs encoding monomeric human PlGF-1, PlGF-2 and PlGF-3 isoform precursors containing 149, 179 and 219 amino acid residues, respectively, have been described. In normal mouse tissues, only one mouse PlGF mRNA encoding the equivalent of human PlGF-2 has been identified. Mouse PlGF shares 65% amino acid identity with human PlGF-2. The gene for PlGF has been mapped to mouse chromosome 12 and human chromosome 14. PlGF binds with high affinity to Flt1, but not to Flk1/KDR.

Mouse PlGF Recombinant Protein

M30-020 20 µg
EUR 313.95
Description: Placenta growth factor (PlGF) is a member of the vascular endothelial growth factor (VEGF) family of growth factors. PlGF and VEGF share primary structural as well as limited amino acid sequence homology with the A and B chains of PDGF. All eight cysteine residues involved in intra and interchain disulfides are conserved among these growth factors. As a result of alternative splicing, three PlGF RNAs encoding monomeric human PlGF1, PlGF2 and PlGF3 isoform precursors containing 149, 179 and 219 amino acid residues, respectively, have been described. In normal mouse tissues, only one mouse PlGF mRNA encoding the equivalent of human PlGF2 has been identified. Mouse PlGF shares 65% amino acid identity with human PlGF2. The gene for PlGF has been mapped to mouse chromosome 12 and human chromosome 14. PlGF binds with high affinity to Flt1, but not to Flk1/KDR.

PLGF (Mouse, monoclonal, antagonistic)

mP1002r-m 100ug
EUR 467.5

Mouse PLGF-2 PicoKine ELISA Kit

EK0863 96 wells
EUR 510
Description: For Quantitative Detection of mouse PLGF-2 in cell culture supernates, serum and plasma (heparin, EDTA).

Anti-Rat PlGF Antibody

104-PA04AG 50 µg
EUR 157.5
Description: Placenta growth factor (PlGF) is a member of the vascular endothelial growth factor (VEGF) family of growth factors. PlGF and VEGF share primary structural as well as limited amino acid sequence homology with the A and B chains of PDGF. All eight cysteine residues involved in intra and interchain disulfides are conserved among these growth factors. As a result of alternative splicing, three PlGF RNAs encoding monomeric human PlGF1, PlGF2 and PlGF3 isoform precursors containing 149, 179 and 219 amino acid residues, respectively, have been described. In normal mouse tissues, only one mouse PlGF mRNA encoding the equivalent of human PlGF2 has been identified. Mouse PlGF shares 65% amino acid identity with human PlGF2. The gene for PlGF has been mapped to mouse chromosome 12 and human chromosome 14. PlGF binds with high affinity to Flt1, but not to Flk1/KDR.

Anti-Rat PlGF Antibody

104-PA04S 100 µg
EUR 126
Description: Placenta growth factor (PlGF) is a member of the PDGF/VEGF family of growth factors that share a conserved pattern of eight cysteines. Alternate splicing results in at least three human mature PlGF forms containing 131 (PlGF-1), 152 (PlGF-2), and 203 (PlGF-3) amino acids (aa) respectively. Only PlGF-2 contains a highly basic heparin-binding 21 aa insert at the C-terminus. In rat only one PlGF that is the equivalent of human PlGF-2 has been identified. Rat PlGF shares 60%, 92%, 62% and 59% aa identity with the appropriate isoform of human, mouse, canine and equine PlGF. PlGF is mainly found as variably glycosylated, secreted, 55 - 60 kDa disulfide linked homodimers. Mammalian cells expressing PlGF include villous trophoblasts, decidual cells, erythroblasts, keratinocytes and some endothelial cells. Circulating PlGF increases during human pregnancy, reaching a peak in mid-gestation; this increase is attenuated in preeclampsia. However, deletion of PlGF in the mouse does not affect development or reproduction. Postnatally, mice lacking PlGF show impaired angiogenesis in response to ischemia. PlGF binds and signals through VEGF R1/Flt-1, but not VEGF R2/Flk-1/KDR, while VEGF binds both but signals only through the angiogenic receptor, VEGF R2. PlGF and VEGF therefore compete for binding to VEGF R1, allowing high PlGF to discourage VEGF/VEGF R1 binding and promote VEGF/VEGF R2-mediated angiogenesis. However, PlGF (especially human PlGF-1) and some forms of VEGF can form dimers that decrease the angiogenic effect of VEGF on VEGF R2. PlGF-2, like VEGF164/165, shows heparin-dependent binding of neuropilin (Npn)-1 and Npn-2 and can inhibit nerve growth cone collapse. PlGF induces monocyte activation, migration, and production of inflammatory cytokines and VEGF. These activities facilitate wound and bone fracture healing, but also contribute to inflammation in active sickle cell disease and atherosclerosis. Circulating PlGF often correlates with tumor stage and aggressiveness, and therapeutic PlGF antibodies are being investigated to inhibit tumor growth and angiogenesis.

PLGF (PGF) mouse monoclonal antibody, clone PLGF94, Purified

AM50307PU-S 100 µg Ask for price

PLGF (PGF) mouse monoclonal antibody, clone PLGF94, Purified

AM50307PU-T 20 µg Ask for price

Rabbit anti PlGF (human)

102-PA04AG 50ug
EUR 240

Rabbit anti PlGF (human)

102-PA04S 100ug
EUR 240

Rabbit Anti-Rat PlGF

104-PA04 100ug
EUR 240

Anti-Human PlGF Antibody

101-M03 100 µg
EUR 378
Description: Placenta growth factor (PlGF) is a member of the PDGF/VEGF family of growth factors that share a conserved pattern of eight cysteines. Alternate splicing results in at least three human mature PlGF forms containing 131 (PlGF1), 152 (PlGF2), and 203 (PlGF3) amino acids (aa) respectively. Only PlGF2 contains a highly basic heparinbinding 21 aa insert at the C-terminus. In the mouse, only one P lGF that is the equivalent of human PlGF2 has been identified. Human PlGF1 shares 56%, 55%, 74% and 95% aa identity with the appropriate isoform of mouse, rat, canine and equine PlGF. PlGF is mainly found as variably glycosylated, secreted, 55 - 60 kDa disulfide linked homodimers. Mammalian cells expressing PlGF include villous trophoblasts, decidual cells, erythroblasts, keratinocytes and some endothelial cells. Circulating PlGF increases during pregnancy, reaching a peak in mid-gestation; this increase is attenuated in preeclampsia. However, deletion of PlGF in the mouse does not affect development or reproduction. Postnatally, mice lacking PlGF show impaired angiogenesis in response to ischemia. PlGF binds and signals through VEGF R1/Flt1, but not VEGF R2/Flk-1/KDR, while VEGF binds both but signals only through the angiogenic receptor, VEGF R2. PlGF and VEGF therefore compete for binding to VEGF R1, allowing high PlGF to discourage VEGF/VEGF R1 binding and promote VEGF/VEGF R2mediated angiogenesis. However, PlGF (especially PlGF1) and some forms of VEGF can form dimers that decrease the angiogenic effect of VEGF on VEGF R2. PlGF2, but not PLGF-1, shows heparindependent binding of neuropilin (Npn)-1 and Npn2. PlGF induces monocyte activation, migration, and production of inflammatory cytokines and VEGF. These activities facilitate wound and bone fracture healing, but also contribute to inflammation in active sickle cell disease and atherosclerosis.

Anti-Human PlGF Antibody

101-M67 100 µg
EUR 189
Description: Placenta growth factor (PlGF) is a member of the PDGF/VEGF family of growth factors that share a conserved pattern of eight cysteines. Alternate splicing results in at least three human mature PlGF forms containing 131 (PlGF1), 152 (PlGF2), and 203 (PlGF3) amino acids (aa) respectively. Only PlGF2 contains a highly basic heparinbinding 21 aa insert at the C-terminus. In the mouse, only one P lGF that is the equivalent of human PlGF2 has been identified. Human PlGF1 shares 56%, 55%, 74% and 95% aa identity with the appropriate isoform of mouse, rat, canine and equine PlGF. PlGF is mainly found as variably glycosylated, secreted, 55 - 60 kDa disulfide linked homodimers. Mammalian cells expressing PlGF include villous trophoblasts, decidual cells, erythroblasts, keratinocytes and some endothelial cells. Circulating PlGF increases during pregnancy, reaching a peak in mid-gestation; this increase is attenuated in preeclampsia. However, deletion of PlGF in the mouse does not affect development or reproduction. Postnatally, mice lacking PlGF show impaired angiogenesis in response to ischemia. PlGF binds and signals through VEGF R1/Flt1, but not VEGF R2/Flk-1/KDR, while VEGF binds both but signals only through the angiogenic receptor, VEGF R2. PlGF and VEGF therefore compete for binding to VEGF R1, allowing high PlGF to discourage VEGF/VEGF R1 binding and promote VEGF/VEGF R2mediated angiogenesis. However, PlGF (especially PlGF1) and some forms of VEGF can form dimers that decrease the angiogenic effect of VEGF on VEGF R2. PlGF2, but not PLGF-1, shows heparindependent binding of neuropilin (Npn)-1 and Npn2. PlGF induces monocyte activation, migration, and production of inflammatory cytokines and VEGF. These activities facilitate wound and bone fracture healing, but also contribute to inflammation in active sickle cell disease and atherosclerosis.

Anti-Human PlGF Antibody

101-M69 100 µg
EUR 189
Description: Placenta growth factor (PlGF) is a member of the PDGF/VEGF family of growth factors that share a conserved pattern of eight cysteines. Alternate splicing results in at least three human mature PlGF forms containing 131 (PlGF1), 152 (PlGF2), and 203 (PlGF3) amino acids (aa) respectively. Only PlGF2 contains a highly basic heparinbinding 21 aa insert at the C-terminus. In the mouse, only one P lGF that is the equivalent of human PlGF2 has been identified. Human PlGF1 shares 56%, 55%, 74% and 95% aa identity with the appropriate isoform of mouse, rat, canine and equine PlGF. PlGF is mainly found as variably glycosylated, secreted, 55 - 60 kDa disulfide linked homodimers. Mammalian cells expressing PlGF include villous trophoblasts, decidual cells, erythroblasts, keratinocytes and some endothelial cells. Circulating PlGF increases during pregnancy, reaching a peak in mid-gestation; this increase is attenuated in preeclampsia. However, deletion of PlGF in the mouse does not affect development or reproduction. Postnatally, mice lacking PlGF show impaired angiogenesis in response to ischemia. PlGF binds and signals through VEGF R1/Flt1, but not VEGF R2/Flk-1/KDR, while VEGF binds both but signals only through the angiogenic receptor, VEGF R2. PlGF and VEGF therefore compete for binding to VEGF R1, allowing high PlGF to discourage VEGF/VEGF R1 binding and promote VEGF/VEGF R2mediated angiogenesis. However, PlGF (especially PlGF1) and some forms of VEGF can form dimers that decrease the angiogenic effect of VEGF on VEGF R2. PlGF2, but not PLGF-1, shows heparindependent binding of neuropilin (Npn)-1 and Npn2. PlGF induces monocyte activation, migration, and production of inflammatory cytokines and VEGF. These activities facilitate wound and bone fracture healing, but also contribute to inflammation in active sickle cell disease and atherosclerosis.

Anti-Human PlGF Antibody

101-MBi67 50 µg
EUR 189
Description: Placenta growth factor (PlGF) is a member of the PDGF/VEGF family of growth factors that share a conserved pattern of eight cysteines. Alternate splicing results in at least three human mature PlGF forms containing 131 (PlGF1), 152 (PlGF2), and 203 (PlGF3) amino acids (aa) respectively. Only PlGF2 contains a highly basic heparinbinding 21 aa insert at the C-terminus. In the mouse, only one P lGF that is the equivalent of human PlGF2 has been identified. Human PlGF1 shares 56%, 55%, 74% and 95% aa identity with the appropriate isoform of mouse, rat, canine and equine PlGF. PlGF is mainly found as variably glycosylated, secreted, 55 - 60 kDa disulfide linked homodimers. Mammalian cells expressing PlGF include villous trophoblasts, decidual cells, erythroblasts, keratinocytes and some endothelial cells. Circulating PlGF increases during pregnancy, reaching a peak in mid-gestation; this increase is attenuated in preeclampsia. However, deletion of PlGF in the mouse does not affect development or reproduction. Postnatally, mice lacking PlGF show impaired angiogenesis in response to ischemia. PlGF binds and signals through VEGF R1/Flt1, but not VEGF R2/Flk-1/KDR, while VEGF binds both but signals only through the angiogenic receptor, VEGF R2. PlGF and VEGF therefore compete for binding to VEGF R1, allowing high PlGF to discourage VEGF/VEGF R1 binding and promote VEGF/VEGF R2mediated angiogenesis. However, PlGF (especially PlGF1) and some forms of VEGF can form dimers that decrease the angiogenic effect of VEGF on VEGF R2. PlGF2, but not PLGF-1, shows heparindependent binding of neuropilin (Npn)-1 and Npn2. PlGF induces monocyte activation, migration, and production of inflammatory cytokines and VEGF. These activities facilitate wound and bone fracture healing, but also contribute to inflammation in active sickle cell disease and atherosclerosis.

Anti-Human PlGF Antibody

102-P248 100 µg
EUR 245.7
Description: Placenta growth factor (PlGF) is a member of the PDGF/VEGF family of growth factors that share a conserved pattern of eight cysteines. Alternate splicing results in at least three human mature PlGF forms containing 131 (PlGF1), 152 (PlGF2), and 203 (PlGF3) amino acids (aa) respectively. Only PlGF2 contains a highly basic heparinbinding 21 aa insert at the C-terminus. In the mouse, only one P lGF that is the equivalent of human PlGF2 has been identified. Human PlGF1 shares 56%, 55%, 74% and 95% aa identity with the appropriate isoform of mouse, rat, canine and equine PlGF. PlGF is mainly found as variably glycosylated, secreted, 55 - 60 kDa disulfide linked homodimers. Mammalian cells expressing PlGF include villous trophoblasts, decidual cells, erythroblasts, keratinocytes and some endothelial cells. Circulating PlGF increases during pregnancy, reaching a peak in mid-gestation; this increase is attenuated in preeclampsia. However, deletion of PlGF in the mouse does not affect development or reproduction. Postnatally, mice lacking PlGF show impaired angiogenesis in response to ischemia. PlGF binds and signals through VEGF R1/Flt1, but not VEGF R2/Flk-1/KDR, while VEGF binds both but signals only through the angiogenic receptor, VEGF R2. PlGF and VEGF therefore compete for binding to VEGF R1, allowing high PlGF to discourage VEGF/VEGF R1 binding and promote VEGF/VEGF R2mediated angiogenesis. However, PlGF (especially PlGF1) and some forms of VEGF can form dimers that decrease the angiogenic effect of VEGF on VEGF R2. PlGF2, but not PLGF-1, shows heparindependent binding of neuropilin (Npn)-1 and Npn2. PlGF induces monocyte activation, migration, and production of inflammatory cytokines and VEGF. These activities facilitate wound and bone fracture healing, but also contribute to inflammation in active sickle cell disease and atherosclerosis.

Anti-Human PlGF-2 Antibody

101-M65 100 µg
EUR 246.75
Description: Placenta growth factor (PlGF) is a member of the PDGF/VEGF family of growth factors that share a conserved pattern of eight cysteines. Alternate splicing results in at least three human mature PlGF forms containing 131 (PlGF1), 152 (PlGF2), and 203 (PlGF3) amino acids (aa) respectively. Only PlGF2 contains a highly basic heparinbinding 21 aa insert at the C-terminus. In the mouse, only one P lGF that is the equivalent of human PlGF2 has been identified. Human PlGF1 shares 56%, 55%, 74% and 95% aa identity with the appropriate isoform of mouse, rat, canine and equine PlGF. PlGF is mainly found as variably glycosylated, secreted, 55 - 60 kDa disulfide linked homodimers. Mammalian cells expressing PlGF include villous trophoblasts, decidual cells, erythroblasts, keratinocytes and some endothelial cells. Circulating PlGF increases during pregnancy, reaching a peak in mid-gestation; this increase is attenuated in preeclampsia. However, deletion of PlGF in the mouse does not affect development or reproduction. Postnatally, mice lacking PlGF show impaired angiogenesis in response to ischemia. PlGF binds and signals through VEGF R1/Flt1, but not VEGF R2/Flk-1/KDR, while VEGF binds both but signals only through the angiogenic receptor, VEGF R2. PlGF and VEGF therefore compete for binding to VEGF R1, allowing high PlGF to discourage VEGF/VEGF R1 binding and promote VEGF/VEGF R2mediated angiogenesis. However, PlGF (especially PlGF1) and some forms of VEGF can form dimers that decrease the angiogenic effect of VEGF on VEGF R2. PlGF2, but not PLGF-1, shows heparindependent binding of neuropilin (Npn)-1 and Npn2. PlGF induces monocyte activation, migration, and production of inflammatory cytokines and VEGF. These activities facilitate wound and bone fracture healing, but also contribute to inflammation in active sickle cell disease and atherosclerosis.

Anti-Human PlGF-2 Antibody

101-M65A 100 µg
EUR 246.75
Description: Placenta Growth Factor-2 (PlGF-2), a 22 kDa protein consisting of 152 amino acid residues is produced as a homodimer. PlGF is a polypeptide growth factor and a member of the platelet-derived growth factor family but more related to vascular endothelial growth factor (VEGF). PlGF acts only as a weak mitogen for those cell types possessing receptors for binding (e.g. vascular endothelial cells). At least one high-affinity receptor for PlGF (FLT-1 or VEGF-R1) has been demonstrated in different primary cell types (e.g. human umbilical vein endothelial cells and monocytes). In addition to its action as a weak mitogen it is also a chemoattractant for monocytes and endothelial cells. Three different proteins are generated by differential splicing of the human PlGF gene: PlGF-1 (131aa native chain), PlGF-2 (152aa) and PlGF-3 (203aa). All 3 mitogens are secretable proteins, but PlGF-2 can bind to heparin with high affinity. PlGF is apparently a homodimer, but preparations of PlGF show some heterogeneity on SDS gels depending of the varying degrees of glycosylation. All dimeric forms possess similar biological activities. Heterodimers between VEGF and PlGF are mitogenic for endothelial cells and have strong angiogenic activity in vivo (e.g. in the CAM assay or in the cornea pocket assay). Different cells and tissues (e.g. placenta) express PlGF-1 and PlGF-2 at different rates. A much related protein of PlGF is VEGF with about 53% homology and VEGF-B with similar biological activities.

Mouse PLGF / PGF Protein, His Tag

PGF-M52H0 50ug
EUR 3327.7
Description: Mouse PLGF, His Tag (PGF-M52H0) is expressed from human 293 cells (HEK293). It contains AA Val 19 - Pro 158 (Accession # P49764-1).

PLGF(PLGF93) Antibody

BNC810093-100 100uL
EUR 238.8
Description: Primary antibody against PLGF(PLGF93), CF680R conjugate, Concentration: 0.1mg/mL

PLGF(PLGF93) Antibody

BNC810093-500 500uL
EUR 652.8
Description: Primary antibody against PLGF(PLGF93), CF680R conjugate, Concentration: 0.1mg/mL

PLGF(PLGF94) Antibody

BNC810094-100 100uL
EUR 238.8
Description: Primary antibody against PLGF(PLGF94), CF680R conjugate, Concentration: 0.1mg/mL

PLGF(PLGF94) Antibody

BNC810094-500 500uL
EUR 652.8
Description: Primary antibody against PLGF(PLGF94), CF680R conjugate, Concentration: 0.1mg/mL

PLGF(PLGF93) Antibody

BNC430093-100 100uL
EUR 238.8
Description: Primary antibody against PLGF(PLGF93), CF543 conjugate, Concentration: 0.1mg/mL

PLGF(PLGF93) Antibody

BNC430093-500 500uL
EUR 652.8
Description: Primary antibody against PLGF(PLGF93), CF543 conjugate, Concentration: 0.1mg/mL

PLGF(PLGF94) Antibody

BNC430094-100 100uL
EUR 238.8
Description: Primary antibody against PLGF(PLGF94), CF543 conjugate, Concentration: 0.1mg/mL

PLGF(PLGF94) Antibody

BNC430094-500 500uL
EUR 652.8
Description: Primary antibody against PLGF(PLGF94), CF543 conjugate, Concentration: 0.1mg/mL

PLGF(PLGF93) Antibody

BNC050093-100 100uL
EUR 238.8
Description: Primary antibody against PLGF(PLGF93), CF405M conjugate, Concentration: 0.1mg/mL

PLGF(PLGF93) Antibody

BNC050093-500 500uL
EUR 652.8
Description: Primary antibody against PLGF(PLGF93), CF405M conjugate, Concentration: 0.1mg/mL

PLGF(PLGF94) Antibody

BNC050094-100 100uL
EUR 238.8
Description: Primary antibody against PLGF(PLGF94), CF405M conjugate, Concentration: 0.1mg/mL

PLGF(PLGF94) Antibody

BNC050094-500 500uL
EUR 652.8
Description: Primary antibody against PLGF(PLGF94), CF405M conjugate, Concentration: 0.1mg/mL

PLGF(PLGF93) Antibody

BNC550093-100 100uL
EUR 238.8
Description: Primary antibody against PLGF(PLGF93), CF555 conjugate, Concentration: 0.1mg/mL

PLGF(PLGF93) Antibody

BNC550093-500 500uL
EUR 652.8
Description: Primary antibody against PLGF(PLGF93), CF555 conjugate, Concentration: 0.1mg/mL

PLGF(PLGF94) Antibody

BNC550094-100 100uL
EUR 238.8
Description: Primary antibody against PLGF(PLGF94), CF555 conjugate, Concentration: 0.1mg/mL

PLGF(PLGF94) Antibody

BNC550094-500 500uL
EUR 652.8
Description: Primary antibody against PLGF(PLGF94), CF555 conjugate, Concentration: 0.1mg/mL

PLGF(PLGF93) Antibody

BNC610093-100 100uL
EUR 238.8
Description: Primary antibody against PLGF(PLGF93), CF660R conjugate, Concentration: 0.1mg/mL

PLGF(PLGF93) Antibody

BNC610093-500 500uL
EUR 652.8
Description: Primary antibody against PLGF(PLGF93), CF660R conjugate, Concentration: 0.1mg/mL

PLGF(PLGF94) Antibody

BNC610094-100 100uL
EUR 238.8
Description: Primary antibody against PLGF(PLGF94), CF660R conjugate, Concentration: 0.1mg/mL

PLGF(PLGF94) Antibody

BNC610094-500 500uL
EUR 652.8
Description: Primary antibody against PLGF(PLGF94), CF660R conjugate, Concentration: 0.1mg/mL

PLGF(PLGF93) Antibody

BNC800093-100 100uL
EUR 238.8
Description: Primary antibody against PLGF(PLGF93), CF680 conjugate, Concentration: 0.1mg/mL

PLGF(PLGF93) Antibody

BNC800093-500 500uL
EUR 652.8
Description: Primary antibody against PLGF(PLGF93), CF680 conjugate, Concentration: 0.1mg/mL

PLGF(PLGF94) Antibody

BNC800094-100 100uL
EUR 238.8
Description: Primary antibody against PLGF(PLGF94), CF680 conjugate, Concentration: 0.1mg/mL

PLGF(PLGF94) Antibody

BNC800094-500 500uL
EUR 652.8
Description: Primary antibody against PLGF(PLGF94), CF680 conjugate, Concentration: 0.1mg/mL

PLGF(PLGF93) Antibody

BNC700093-100 100uL
EUR 238.8
Description: Primary antibody against PLGF(PLGF93), CF770 conjugate, Concentration: 0.1mg/mL

PLGF(PLGF93) Antibody

BNC700093-500 500uL
EUR 652.8
Description: Primary antibody against PLGF(PLGF93), CF770 conjugate, Concentration: 0.1mg/mL

PLGF(PLGF94) Antibody

BNC700094-100 100uL
EUR 238.8
Description: Primary antibody against PLGF(PLGF94), CF770 conjugate, Concentration: 0.1mg/mL

PLGF(PLGF94) Antibody

BNC700094-500 500uL
EUR 652.8
Description: Primary antibody against PLGF(PLGF94), CF770 conjugate, Concentration: 0.1mg/mL

PLGF(PLGF93) Antibody

BNCP0093-250 250uL
EUR 459.6
Description: Primary antibody against PLGF(PLGF93), PerCP conjugate, Concentration: 0.1mg/mL

PLGF(PLGF94) Antibody

BNCP0094-250 250uL
EUR 459.6
Description: Primary antibody against PLGF(PLGF94), PerCP conjugate, Concentration: 0.1mg/mL

PLGF(PLGF93) Antibody

BNCR0093-250 250uL
EUR 459.6
Description: Primary antibody against PLGF(PLGF93), RPE conjugate, Concentration: 0.1mg/mL

PLGF(PLGF94) Antibody

BNCR0094-250 250uL
EUR 459.6
Description: Primary antibody against PLGF(PLGF94), RPE conjugate, Concentration: 0.1mg/mL

PLGF(PLGF93) Antibody

BNCA0093-250 250uL
EUR 459.6
Description: Primary antibody against PLGF(PLGF93), APC conjugate, Concentration: 0.1mg/mL

PLGF(PLGF94) Antibody

BNCA0094-250 250uL
EUR 459.6
Description: Primary antibody against PLGF(PLGF94), APC conjugate, Concentration: 0.1mg/mL

PLGF(PLGF93) Antibody

BNCAP0093-100 100uL
EUR 238.8
Description: Primary antibody against PLGF(PLGF93), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL

PLGF(PLGF93) Antibody

BNCAP0093-500 500uL
EUR 652.8
Description: Primary antibody against PLGF(PLGF93), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL

PLGF(PLGF94) Antibody

BNCAP0094-100 100uL
EUR 238.8
Description: Primary antibody against PLGF(PLGF94), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL

PLGF(PLGF94) Antibody

BNCAP0094-500 500uL
EUR 652.8
Description: Primary antibody against PLGF(PLGF94), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL

PLGF(PLGF93) Antibody

BNCH0093-100 100uL
EUR 238.8
Description: Primary antibody against PLGF(PLGF93), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL

PLGF(PLGF93) Antibody

BNCH0093-500 500uL
EUR 652.8
Description: Primary antibody against PLGF(PLGF93), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL

PLGF(PLGF94) Antibody

BNCH0094-100 100uL
EUR 238.8
Description: Primary antibody against PLGF(PLGF94), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL

PLGF(PLGF94) Antibody

BNCH0094-500 500uL
EUR 652.8
Description: Primary antibody against PLGF(PLGF94), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL

OKRC01283-96W - PLGF-2 ELISA Kit (Mouse)

OKRC01283-96W 96Wells
EUR 525

Anti-Human PlGF (native) Antibody

102-PABi04 50 µg
EUR 157.5
Description: Placenta growth factor (PlGF) is a member of the PDGF/VEGF family of growth factors that share a conserved pattern of eight cysteines. Alternate splicing results in at least three human mature PlGF forms containing 131 (PlGF1), 152 (PlGF2), and 203 (PlGF3) amino acids (aa) respectively. Only PlGF2 contains a highly basic heparinbinding 21 aa insert at the C-terminus. In the mouse, only one P lGF that is the equivalent of human PlGF2 has been identified. Human PlGF1 shares 56%, 55%, 74% and 95% aa identity with the appropriate isoform of mouse, rat, canine and equine PlGF. PlGF is mainly found as variably glycosylated, secreted, 55 - 60 kDa disulfide linked homodimers. Mammalian cells expressing PlGF include villous trophoblasts, decidual cells, erythroblasts, keratinocytes and some endothelial cells. Circulating PlGF increases during pregnancy, reaching a peak in mid-gestation; this increase is attenuated in preeclampsia. However, deletion of PlGF in the mouse does not affect development or reproduction. Postnatally, mice lacking PlGF show impaired angiogenesis in response to ischemia. PlGF binds and signals through VEGF R1/Flt1, but not VEGF R2/Flk-1/KDR, while VEGF binds both but signals only through the angiogenic receptor, VEGF R2. PlGF and VEGF therefore compete for binding to VEGF R1, allowing high PlGF to discourage VEGF/VEGF R1 binding and promote VEGF/VEGF R2mediated angiogenesis. However, PlGF (especially PlGF1) and some forms of VEGF can form dimers that decrease the angiogenic effect of VEGF on VEGF R2. PlGF2, but not PLGF-1, shows heparindependent binding of neuropilin (Npn)-1 and Npn2. PlGF induces monocyte activation, migration, and production of inflammatory cytokines and VEGF. These activities facilitate wound and bone fracture healing, but also contribute to inflammation in active sickle cell disease and atherosclerosis.

PLGF

E8EM1701-88 100ul
EUR 275
Description: Available in various conjugation types.

PLGF

E8EM1701-90 100ul
EUR 275
Description: Available in various conjugation types.

PLGF

E8ER1706-88 100ul
EUR 275
Description: Available in various conjugation types.

PLGF

E8ET1704-99 100ul
EUR 275
Description: Available in various conjugation types.

PLGF

PA1066 100μg
EUR 260

PLGF

PA1066-M 100μg
EUR 290
Description: Polyclonal Antibodies Conjugated to Magnetic Beads

PLGF

PA1066-S 100μg
EUR 290
Description: Polyclonal Antibodies Conjugated to Sepharose Beads

Anti-Human PlGF (Peptide) Antibody

102-PA01S 100 µg
EUR 115.5
Description: Placenta growth factor (PlGF) is a member of the PDGF/VEGF family of growth factors that share a conserved pattern of eight cysteines. Alternate splicing results in at least three human mature PlGF forms containing 131 (PlGF1), 152 (PlGF2), and 203 (PlGF3) amino acids (aa) respectively. Only PlGF2 contains a highly basic heparinbinding 21 aa insert at the C-terminus. In the mouse, only one P lGF that is the equivalent of human PlGF2 has been identified. Human PlGF1 shares 56%, 55%, 74% and 95% aa identity with the appropriate isoform of mouse, rat, canine and equine PlGF. PlGF is mainly found as variably glycosylated, secreted, 55 - 60 kDa disulfide linked homodimers. Mammalian cells expressing PlGF include villous trophoblasts, decidual cells, erythroblasts, keratinocytes and some endothelial cells. Circulating PlGF increases during pregnancy, reaching a peak in mid-gestation; this increase is attenuated in preeclampsia. However, deletion of PlGF in the mouse does not affect development or reproduction. Postnatally, mice lacking PlGF show impaired angiogenesis in response to ischemia. PlGF binds and signals through VEGF R1/Flt1, but not VEGF R2/Flk-1/KDR, while VEGF binds both but signals only through the angiogenic receptor, VEGF R2. PlGF and VEGF therefore compete for binding to VEGF R1, allowing high PlGF to discourage VEGF/VEGF R1 binding and promote VEGF/VEGF R2mediated angiogenesis. However, PlGF (especially PlGF1) and some forms of VEGF can form dimers that decrease the angiogenic effect of VEGF on VEGF R2. PlGF2, but not PLGF-1, shows heparindependent binding of neuropilin (Npn)-1 and Npn2. PlGF induces monocyte activation, migration, and production of inflammatory cytokines and VEGF. These activities facilitate wound and bone fracture healing, but also contribute to inflammation in active sickle cell disease and atherosclerosis.

Rabbit Anti-Human PlGF (native)

102-PA04 100ug
EUR 240

Polyclonal Anti-PGF (PLGF) Antibody

GWB-BBP088 0.1 mg Ask for price

Rabbit Anti-Human PlGF (Peptide)

102-PA01 100ug
EUR 240

PLGF Antibody

49602 100ul
EUR 499

PLGF Antibody

49602-100ul 100ul
EUR 399.6

PLGF Antibody

49602-50ul 50ul
EUR 286.8

PLGF Antibody

E8RT1505 100ul
EUR 225
Description: Available in various conjugation types.

PlGF antibody

70R-12427 100 ug
EUR 371
Description: Rabbit polyclonal PlGF antibody

PlGF Antibody

5743-100 each
EUR 405.6

PlGF Antibody

5743-30T each
EUR 175.2

PLGF Antibody

GWB-628116 0.1 mg Ask for price

PLGF Antibody

R30247 100 ug
EUR 356.15
Description: Placental growth factor(PGF, also known as PLGF) codes for an angiogenic factor expressed in placental tissue that is similar to vascular permeability factor/vascular endothelial growth factor(VPF/VEGF). It is a glycosylated dimeric secreted protein able to stimulate endothelial cell growth in vitro. PGF is located on chromosome 14 and has been conserved in evolution. It belongs to the family of vascular endothelial growth factors(VEGFs) and binds to the flt-1 VEGF receptor. PLGF-2, which is a PLGF isoform, binds neuropilin-1 and 2 in a heparin-dependent manner. PGF regulates inter- and intra molecular cross talk between the VEGF RTKs Flt1 and Flk1 and stimulates the phosphorylation of specific Flt1 tyrosine residues and the expression of distinct downstream target genes. Moreover, it plays an important role in pathological angiogenic events and with exerting its biological activities through binding to VEGFR1.

PLGF Antibody

R34945-100UG 100 ug
EUR 339.15
Description: Additional name(s) for this target protein: Placental growth factor; PGF

Sheep Polyclonal anti-human PlGF

hAP-5406 50ug
EUR 400

PlGF-1 Antibody

5739-100 each
EUR 405.6

PlGF-1 Antibody

5739-30T each
EUR 175.2

Mouse Placenta Growth Factor (PLGF) Protein

20-abx068553
  • Ask for price
  • Ask for price
  • Ask for price
  • Ask for price
  • Ask for price
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug

Mouse Placenta Growth Factor (PLGF) Protein

abx068553-20g 20 µg
EUR 562.5

Mouse Placenta Growth Factor (PLGF) Protein

abx068553-5g 5 µg
EUR 287.5

Placenta Growth Factor (PLGF) Polyclonal Antibody (Mouse)

4-PAA114Mu01
  • Ask for price
  • Ask for price
  • Ask for price
  • Ask for price
  • Ask for price
  • 100ul
  • 10ml
  • 1ml
  • 200ul
  • 20ul
Description: A Rabbit polyclonal antibody against Mouse Placenta Growth Factor (PLGF)

Leave a Reply

Your email address will not be published. Required fields are marked *